1. Short title This Act may be cited as the Drug-Price Transparency in Communications Act . 2. Findings Congress finds as follows: (1) Direct-to-consumer advertising of prescription pharmaceuticals is legal in only 2 developed countries, the United States and New Zealand. (2) Direct-to-consumer advertising of prescription pharmaceuticals is designed to cause patients to pressure physicians to prescribe certain medications. (3) In 2015, pharmaceutical companies spent more than $100,000,000 on advertising with respect to each of 16 brand-name drugs, primarily new and expensive drugs. (4) Prescription rates of medications advertised directly to consumers have increased by 34.2 percent compared to a 5.1 percent increase in other pharmaceuticals. (5) Prescription pharmaceuticals cost more in the United States than they do in any other country. (6) The American Medical Association has passed resolutions calling for the ban of direct-to-consumer advertising of prescription pharmaceuticals, and to require price transparency in any direct-to-consumer advertising. (7) The amount of spending by pharmaceutical companies in marketing to health care providers is more than 4 times the spending for direct-to-consumer advertising. (8) Health care providers are more likely to prescribe a certain drug if they have received payments or marketing materials from the manufacturer of that drug. 3. Price disclosure requirement for direct-to-consumer drug advertisements (a) In general Section 303(g)(1) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 333(g)(1) ) is amended— (1) by striking (A) and inserting (i) ; (2) by striking (B) and inserting (ii); (3) by striking (1) With respect and inserting (1)(A) With respect ; (4) by striking this paragraph each place it appears and inserting this subparagraph